Zynerba Pharmaceuticals

A clinical-stage pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs

Learn More

Our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, Fragile X syndrome, fibromyalgia and peripheral neuropathic pain through synthetic cannabinoid therapeutics formulated for transdermal delivery.

Our Team

Our Team

Our team has a proven track record of success in developing novel transdermal products for patients in need.

More >>

Our Development Pipeline

Our Development Pipeline

We are developing two proprietary products: a transdermal synthetic CBD gel for refractory epilepsy, osteoarthritis and Fragile X syndrome and a novel synthetic THC pro-drug transdermal patch for two pain indications – fibromyalgia and peripheral neuropathic pain.

More >>

For Investors

For Investors

Learn more about our company and our potential.

More >>

Latest News

1208

Zynerba Pharmaceuticals to Host Clinical Research Day on December 15, 2016 to Discuss the Role of ZYN002 CBD Gel in Multiple Diseases

Learn More

1205

Zynerba Reports Positive Results for ZYN002 CBD Gel in Phase 1 Studies at 70th Annual Meeting of the American Epilepsy Society

Learn More